$SCTX News
Last published 15h ago
- 15h agoSCTXScribe Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoSCTXScribe Therapeutics to Participate in Upcoming Healthcare Investor ConferencesGlobeNewswireALAMEDA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics" or "the Company") (NASDAQ:SCTX), a clinical-stage biotechnology company engineering purpose-built in
- 1w agoSCTXScribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026GlobeNewswireLate-breaking presentation will report long-term durability preclinical data for STX-1150, Scribe’s lead epigenetic silencing therapy for LDL cholesterol reduction now in clinical trials A second presentation will
- 2mo agoSCTXScribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswireInitiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering
- 2mo agoSCTXScribe Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (NASDAQ:SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies
- 3mo agoSCTXScribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private PlacementGlobeNewswireALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (NASDAQ:SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies
- 3mo agoSCTXScribe Therapeutics Announces Pricing of Upsized Initial Public OfferingGlobeNewswireALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (NASDAQ:SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies